Henry Schein (NASDAQ:HSIC)‘s stock had its “buy” rating restated by investment analysts at Craig Hallum in a report issued on Wednesday, The Fly reports. They currently have a $77.00 target price on the stock, up from their previous target price of $72.00. Craig Hallum’s price objective would suggest a potential upside of 16.24% from the company’s previous close.
Several other research firms also recently commented on HSIC. Zacks Investment Research downgraded Henry Schein from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th. UBS Group began coverage on Henry Schein in a research note on Thursday, January 17th. They issued a “sell” rating and a $73.00 price target on the stock. ValuEngine cut Henry Schein from a “hold” rating to a “sell” rating in a research note on Tuesday, January 29th. BidaskClub cut Henry Schein from a “hold” rating to a “sell” rating in a research note on Tuesday, January 29th. Finally, Royal Bank of Canada dropped their price target on Henry Schein to $69.00 and set a “sector perform” rating on the stock in a research note on Tuesday, February 12th. Six analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. Henry Schein currently has a consensus rating of “Hold” and an average price target of $77.93.
NASDAQ:HSIC traded down $0.47 on Wednesday, hitting $66.24. 14,823 shares of the stock were exchanged, compared to its average volume of 1,836,327. The stock has a market capitalization of $9.45 billion, a P/E ratio of 16.00, a P/E/G ratio of 2.35 and a beta of 0.89. Henry Schein has a 52 week low of $56.58 and a 52 week high of $91.35. The company has a current ratio of 1.30, a quick ratio of 0.68 and a debt-to-equity ratio of 0.28.
In related news, Director Philip A. Laskawy sold 3,591 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $59.12, for a total value of $212,299.92. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Philip A. Laskawy sold 1,084 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $59.86, for a total value of $64,888.24. Following the completion of the sale, the director now owns 32,899 shares in the company, valued at approximately $1,969,334.14. The disclosure for this sale can be found here. 1.06% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of HSIC. Atlanta Capital Management Co. L L C increased its position in Henry Schein by 113.9% during the 4th quarter. Atlanta Capital Management Co. L L C now owns 6,254,807 shares of the company’s stock worth $491,127,000 after buying an additional 3,330,154 shares during the period. Boston Partners bought a new position in Henry Schein during the 1st quarter worth $99,903,000. Norges Bank bought a new position in Henry Schein during the 4th quarter worth $114,725,000. BlackRock Inc. increased its position in Henry Schein by 4.6% during the 4th quarter. BlackRock Inc. now owns 11,118,102 shares of the company’s stock worth $872,993,000 after buying an additional 488,210 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Henry Schein by 22.1% during the 1st quarter. JPMorgan Chase & Co. now owns 2,426,917 shares of the company’s stock worth $145,882,000 after buying an additional 439,922 shares during the period.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Recommended Story: S&P 500 Index
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.